CEIRR: SARS-CoV-2 Research Activities

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: RICHARD  WEBBY
Organization: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Fiscal Year: 2024
Award: $602,070
Funding agency: National Institute of Allergy and Infectious Diseases

CEIRR will determine the molecular, ecologic and/or environmental factors that influence the evolution, emergence, transmission and pathogenicity of respiratory viruses, including coronaviruses such as SARS-CoV-2, and characterize the immune response to infection to improve understanding of the immune correlates of protection and cross-protection. CEIRR will carry out a host of activities, including cohort studies and human and animal sampling to further understanding of infection, transmission and vaccination; identification of immunological factors that determine disease outcome in the response to infection and vaccination; and studies to determine how viruses evolve, adapt and transmit between humans and at interspecies interfaces.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Animals><COVID-19 vaccine><COVID-19 virus><COVID19 virus><CoV-2><CoV2><Cohort Studies><Concurrent Studies><Coronaviridae><Coronavirus><Disease Outcome><Environmental Factor><Environmental Risk Factor><Evolution><Human><Immune><Immune response><Immunes><Immunologic Factors><Immunological Factors><Immunological response><Infection><Modern Man><Molecular><Pathogenicity><Research Activity><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Transmission><Vaccination><Virus><Wuhan coronavirus><corona virus><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><cross immunity><cross protection><develop a vaccine><develop vaccines><development of a vaccine><environmental risk><hCoV19><host response><immune system response><immunologic substance><immunological substance><immunoresponse><improved><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><respiratory virus><response><transmission process><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine development><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID>